Integer Holdings Corporation (NYSE: ITGR) faced a downgrade from Wall Street Zen, which shifted its rating from **buy** to **hold** in a research note issued on **October 24, 2023**. This adjustment reflects a broader trend as several financial institutions reassess their outlook on the medical device manufacturer.
Wells Fargo & Company also revised its stance, maintaining an **equal weight** rating while lowering its target price from **$132.00** to **$80.00**. Similarly, Raymond James Financial updated its rating to **outperform**, reducing the price target from **$143.00** to **$95.00**. Citigroup followed suit, increasing its price objective from **$69.00** to **$75.00**, assigning a **neutral** rating. In contrast, Truist Financial raised its price target from **$86.00** to **$95.00**, affirming its **buy** rating. KeyCorp adjusted its target from **$145.00** to **$133.00**, maintaining an **overweight** rating.
Overall, the consensus among analysts indicates a **hold** rating for Integer, with an average price target of **$98.38**, according to data from MarketBeat.com. Among the analysts, four have rated the stock as a **buy**, six as a **hold**, and one as a **sell**.
Recent Earnings Performance
Integer recently reported its quarterly earnings on **October 23, 2023**, revealing earnings per share (EPS) of **$1.79**, surpassing the consensus estimate of **$1.68** by **$0.11**. The company demonstrated a net margin of **4.75%** and a return on equity of **12.84%**, with revenues increasing by **8.4%** compared to the same period last year. For the fiscal year 2025, Integer has set guidance for EPS between **$6.290** and **$6.430**. Analysts predict an EPS of **$6.01** for the current year.
Additionally, Integer’s Board of Directors approved a significant **$200 million** share repurchase plan on **November 4, 2023**. This initiative allows the company to buy back up to **8.3%** of its outstanding shares through open market transactions, typically indicating that the board considers the stock undervalued.
Insider Activity and Institutional Investments
Recent insider trading has also been a point of interest. **Tommy P. Thomas**, the Vice President, sold **884 shares** on **November 11, 2023**, at an average price of **$70.15**, totaling **$62,012.60**. This sale reduced his holding to **3,596 shares**, valued at approximately **$252,259.40**, marking a **19.73%** decrease in his position. Conversely, **Diron Smith**, Executive Vice President, purchased **1,116 shares** on **November 7, 2023**, for an average cost of **$67.19** per share, totaling **$74,984.04**. This acquisition increased his stake to **7,698 shares**, valued at **$517,228.62**, representing a **16.96%** increase.
In the past three months, insiders have collectively purchased **5,843 shares** valued at **$384,771**, holding about **2.16%** of the company.
Institutional investors have also shown significant interest in Integer. **GAMMA Investing LLC** increased its stake by **166.2%** during the fourth quarter, now owning **1,134 shares** valued at **$89,000** after acquiring an additional **708 shares**. **Tudor Investment Corp ET AL** raised its holdings by an astonishing **50,787.5%**, now possessing **29.5 million shares** worth **$28.6 million**. Other notable investments include **CIBC Bancorp USA Inc.**, which acquired a new position valued at **$380,000**, and **CANADA LIFE ASSURANCE Co.**, which increased its holdings by **1.7%**.
As of now, institutional investors and hedge funds control approximately **99.29%** of Integer’s stock, reflecting strong confidence in the company’s future.
Integer Holdings Corporation operates as a global provider of outsourced medical device design, development, and manufacturing solutions. The company collaborates with leading medical technology firms, delivering complex components and finished devices across various therapeutic areas. Its offerings include product design, precision machining, microelectronic assembly, terminal sterilization, and regulatory support, enabling clients to expedite time to market and enhance product performance.
With these adjustments in ratings and insider activities, Integer remains a focal point for investors and analysts alike, as the company navigates the evolving landscape of the medical device sector.
